id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-255208-rbko9ecz	Stevens, Ryan W.	Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2	2020-10-12		.txt	text/plain	2043	108	44	Herein we describe the potential impact of time to therapy initiation on outcomes in patients with COVID-19 and detail the existing data surrounding this topic in relation to remdesivir, convalescent plasma, lopinavir/ritonavir, and hydroxychloroquine. A bulk of published COVID-19 literature to date has consisted of small observational studies, early reports of larger-scale retrospective data, and few randomized, controlled clinical trials. In theory this may also hold true for SARS-CoV-2, where earlier initiation of antiviral therapy during the early postexposure, minimally symptomatic phase, being likely to result in the greatest possible clinical benefit in the form of shortening the duration of illness, viral shedding, modulating the immune response, and subsequent prevention of hospitalization. For example, a study from China demonstrated that patients who received treatment within 6 days of symptom onset demonstrated shorter times to viral clearance as compared to those who received later therapy initiation.	./cache/cord-255208-rbko9ecz.txt	./txt/cord-255208-rbko9ecz.txt